1. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation 
Shomron Ben-Horin, Niels Vande Casteele, Stefan Schreiber, Peter Laszlo Lakatos 
Clinical Gastroenterology and Hepatology 
Volume 14, Issue 12, Pages (December 2016)
DOI: /j.cgh
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
Established and possible mechanisms of action of infliximab and some other anti-TNF monoclonal antibodies in IBD. Binding to tmTNF and sTNF neutralizes the biological effects of TNF, preventing amplification of inflammation that can occur in IBD. Binding to tmTNF also causes reverse signaling and induction of apoptosis and regulatory M2 macrophages, which are thought to possibly play a role in the control of IBD. ADCC and CDC have been suggested but not shown to be a mechanism of action of anti-TNF antibodies. CDC, complement-dependent cytotoxicity; MOA, mechanism of action; NK, natural killer.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions